Clinical validation of the HPV-Risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region

Journal of Clinical Microbiology

Volumn 52, Issue 3, 2014, Pages 890-896

  Hesselink, A T ^a   Berkhof, J ^a   Van Der Salm, M L ^a   Van Splunter, A P ^a   Geelen, T H ^b   Van Kemenade, F J ^c   Bleeker, M G B ^a   Heideman, D A M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN E7; VIRUS DNA;

ADULT; ARTICLE; CANCER GRADING; CANCER SCREENING; CERVICAL SCRAPING SPECIMEN; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; DNA DETERMINATION; FEMALE; HIGH RISK POPULATION; HPV RISK ASSAY; HUMAN; HUMAN TISSUE; INFECTION RISK; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SAMPLING; SCORING SYSTEM; SELF COLLECTED CERVICOVAGINAL SPECIMEN; SENSITIVITY AND SENSIBILITY; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL LAVAGE; VALIDATION STUDY; VIRUS DETECTION; WART VIRUS;

ADULT; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SELF ADMINISTRATION; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

EID: 84894596840     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03195-13     Document Type: Article

References (37)

1. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348: 518-527. http://dx.doi.org/10.1056/NEJMoa021641. (Pubitemid 36159887)
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19. (Pubitemid 29406813)
3. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ. 2012. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 13:78-88. http://dx.doi.org/10.1016/S1470-2045(11)70296-0.
4. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA. 2009. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360:1385-1394. http://dx.doi.org/10. 1056/NEJMoa0808516.
5. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Radberg T, Strander B, Forslund O, Hansson BG, Rylander E, Dillner J. 2007. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357:1589-1597. http://dx.doi.org/10.1056/NEJMoa073204. (Pubitemid 47598401)
6. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL. 2007. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357:1579-1588. http://dx.doi.org/10.1056/NEJMoa071430. (Pubitemid 47598400)
7. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J. 2010. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11:249-257. http://dx.doi.org/10.1016/S1470-2045(09)70360- 2.
8. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DA, Snijders PJ. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 124:516-520. http://dx.doi.org/10.1002/ijc.24010.
9. Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ. 2009. Validation of high-riskHPVtests for primary cervical screening. J. Clin. Virol. 46(Suppl 3):S1-S4. http://dx.doi.org/10.1016/S1386-6532(09)00540-X.
10. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N. 2008. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J. Natl. Cancer Inst. 100:492-501. http://dx.doi.org/10.1093/jnci/djn065.
11. Heideman DA, Hesselink AT, Berkhof J, van Kemenade F, Melchers WJ, Daalmeijer NF, Verkuijten M, Meijer CJ, Snijders PJ. 2011. Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J. Clin. Microbiol. 49:3983-3985. http://dx.doi.org/10.1128/JCM.05552-11.
12. Hesselink AT, Heideman DA, Berkhof J, Topal F, Pol RP, Meijer CJ, Snijders PJ. 2010. Comparison of the clinical performance of Papillo-Check human papillomavirus detection with that of the GP5+/6+-PCRenzyme immunoassay in population-based cervical screening. J. Clin. Microbiol. 48:797-801. http://dx.doi.org/10.1128/JCM.01743-09.
13. Hesselink AT, Meijer CJ, Poljak M, Berkhof J, van Kemenade FJ, van der Salm ML, Bogaarts M, Snijders PJ, Heideman DA. 2013. Clinical validation of the Abbott RealTime High Risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening. J. Clin. Microbiol. 51:2409-2410. http://dx.doi.org/10.1128/JCM.00633-13.
14. Gok M, Heideman DA, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JW, Voorhorst F, Belien JA, Babovic M, Snijders PJ, Meijer CJ. 2010. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 340:c1040. http://dx.doi.org/10.1136/bmj.c1040.
15. Gok M, van Kemenade FJ, Heideman DA, Berkhof J, Rozendaal L, Spruyt JW, Belien JA, Babovic M, Snijders PJ, Meijer CJ. 2012. Experience with high-risk human papillomavirus testing on vaginal brushbased self-samples of non-attendees of the cervical screening program. Int. J. Cancer 130:1128-1135. http://dx.doi.org/10.1002/ijc.26128.
16. Snijders PJ, Verhoef VM, Arbyn M, Ogilvie G, Minozzi S, Banzi R, van Kemenade FJ, Heideman DA, Meijer CJ. 2013. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int. J. Cancer 132:2223-2236. http://dx.doi.org/10.1002/ijc.27790.
17. Belinson JL, Du H, Yang B, Wu R, Belinson SE, Qu X, Pretorius RG, Yi X, Castle PE. 2012. Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing. Int. J. Cancer 130:1855-1860. http://dx.doi.org/ 10.1002/ijc.26202.
18. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. 2002. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J. Clin. Microbiol. 40:779-787. http://dx.doi.org/10.1128/JCM.40.3.779-787.2002. (Pubitemid 34208623)
19. Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Melsheimer P, Kisseljov F, Durst M, Schneider A, von Knebel Doeberitz M. 2008. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 68:307-313. http://dx.doi.org/10.1158/0008-5472.CAN-07-2754. (Pubitemid 351380133)
20. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. 2009. Human papillomaviruses. IARC Monogr. 100B:255-313.
21. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menendez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andujar M, Castellsague X, Sanchez GI, Nowakowski AM, Bornstein J, Munoz N, Bosch FX. 2010. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 11:1048-1056. http://dx.doi.org/10.1016/S1470-2045(10)70230-8.
22. Koopman LA, Szuhai K, van Eendenburg JD, Bezrookove V, Kenter GG, Schuuring E, Tanke H, Fleuren GJ. 1999. Recurrent integration of human papillomaviruses 16, 45, and 67 near translocation breakpoints in new cervical cancer cell lines. Cancer Res. 59:5615-5624. (Pubitemid 29526482)
23. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specificHPVtesting in clinical practice. J. Natl. Cancer Inst. 97:1072-1079. http://dx.doi.org/10.1093/jnci/dji187. (Pubitemid 41417924)
24. Berkhof J, Bulkmans NW, Bleeker MC, Bulk S, Snijders PJ, Voorhorst FJ, Meijer CJ. 2006. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol. Biomarkers Prev. 15:1268-1273. http://dx.doi.org/10.1158/1055-9965.EPI-05-0764. (Pubitemid 44125280)
25. Dijkstra MG, Heideman DA, van Kemenade FJ, Hogewoning KJ, Hesselink AT, Verkuijten MC, van Baal WM, Boer GM, Snijders PJ, Meijer CJ. 2012. Brush-based self-sampling in combination with GP5+/6+-PCR-based hrHPV testing: high concordance with physician-taken cervical scrapes for HPV genotyping and detection of high-grade CIN. J. Clin. Virol. 54:147-151. http://dx.doi.org/10. 1016/j.jcv.2012.02.022.
26. Brink AA, Meijer CJ, Wiegerinck MA, Nieboer TE, Kruitwagen RF, van Kemenade F, Fransen Daalmeijer N, Hesselink AT, Berkhof J, Snijders PJ. 2006. High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J. Clin. Microbiol. 44:2518-2523. http://dx.doi.org/10.1128/JCM.02440-05. (Pubitemid 44092421)
27. de Roda Husman AM, Snijders PJ, Stel HV, van den Brule AJ, Meijer CJ, Walboomers JM. 1995. Processing of long-stored archival cervical smears for human papillomavirus detection by the polymerase chain reaction. Br. J. Cancer 72:412-417.
28. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. 2006. Bead-based multiplex genotyping of human papillomaviruses. J. Clin. Microbiol. 44:504-512. http://dx.doi.org/10.1128/JCM.44.2.504-512.2006. (Pubitemid 43222244)
29. Tang NS, Tang ML, Chan IS. 2003. On tests of equivalence via non-unity relative risk for matched-pair design. Stat. Med. 22:1217-1233. http://dx.doi.org/10.1002/sim.1213. (Pubitemid 36526951)
30. Bhatla N, Singla S, Awasthi D. 2012. Human papillomavirus deoxyribonucleic acid testing in developed countries. Best Pract. Res. Clin. Obstet. Gynaecol. 26:209-220. http://dx.doi.org/10.1016/j.bpobgyn.2011.11.003.
31. Cuzick J, Bergeron C, von Knebel Doeberitz M, Gravitt P, Jeronimo J, Lorincz AT, Meijer LM, Sankaranarayanan R, Snijders JF, Szarewski A. 2012. New technologies and procedures for cervical cancer screening. Vaccine 30(Suppl 5):F107-F116. http://dx.doi.org/10.1016/j.vaccine.2012.05.088.
32. Zhao FH, Lewkowitz AK, Chen F, Lin MJ, Hu SY, Zhang X, Pan QJ, Ma JF, Niyazi M, Li CQ, Li SM, Smith JS, Belinson JL, Qiao YL, Castle PE. 2012. Pooled analysis of a self-sampling HPVDNAtest as a cervical cancer primary screening method. J. Natl. Cancer Inst. 104:178-188. http://dx.doi.org/10.1093/jnci/ djr532.
33. de Bie RP, Schmeink CE, Bakkers JM, Snijders PJ, Quint WG, Massuger LF, Bekkers RL, Melchers WJ. 2011. The indicating FTA elute cartridge a solid sample carrier to detect high-risk HPV and high-grade cervical lesions. J. Mol. Diagn. 13:371-376. http://dx.doi.org/10.1016/j.jmoldx.2011.02.003.
34. Heideman DA, Hesselink AT, van Kemenade FJ, Iftner T, Berkhof J, Topal F, Agard D, Meijer CJ, Snijders PJ. 2013. The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for HPV test requirements for cervical screening. J. Clin. Microbiol. 51:3653-3657. http://dx.doi.org/10.1128/JCM.01517-13.
35. Belinson JL, Wu R, Belinson SE, Qu X, Yang B, Du H, Wu R, Wang C, Zhang L, Zhou Y, Liu Y, Pretorius RG. 2011. A population-based clinical trial comparing endocervical high-risk HPV testing using Hybrid Capture 2 and Cervista from the SHENCCAST II Study. Am. J. Clin. Pathol. 135: 790-795. http://dx.doi.org/10.1309/AJCPKA6ATAPBZ6JQ.
36. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. 2012. The biology and life-cycle of human papillomaviruses. Vaccine 30(Suppl 5):F55-F70. http://dx.doi.org/10.1016/j.vaccine.2012.06.083.
37. Hiller T, Poppelreuther S, Stubenrauch F, Iftner T. 2006. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol. Biomarkers Prev. 15:1262-1267. http://dx.doi.org/10.1158/1055- 9965.EPI-05-0778. (Pubitemid 44125279)